Last Update Time:
05-Mar-2025 16:00:00
ISIN:
INE782E01017
Sector:
Healthcare
Symbol:
HESTERBIO
Hester Biosciences Limited
₹1,433.00
₹5.90
(0.41%)
▲
Prev. Close
₹1,427.10
Open
₹1,427.10
Close
₹1,464.65
Range
₹1,361.35 - ₹1,504.65
High
₹1,495.00
Low
₹1,401.15
Ind. Close
₹0.00
VWAP
₹1,444.69
The current stock price of Hester Biosciences Limited is ₹1,433.00, with a target price range between ₹1,361.35 and ₹1,504.65. The stock has experienced a price change of ₹5.90 (0.41%), reflecting recent market volatility.
Today's opening price was ₹1,427.10, while the previous close stood at ₹1,427.10.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Hester Biosciences Limited Price Chart
Hester Biosciences Limited Pre Open Market Overview: 05-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1427.1
- Previous Close Price: 1427.1
- Change: 0.00%
- Total Traded Volume: 1
- Total Buy Quantity: 488
- Total Sell Quantity: 568
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,390.00 | 9.00 | 0.00 |
| 1,400.10 | 1.00 | 0.00 |
| 1,402.00 | 1.00 | 0.00 |
| 1,410.00 | 144.00 | 0.00 |
| 1,427.10 | 2.00 | 0.00 |
| 1,448.00 | 0.00 | 10.00 |
| 1,448.45 | 0.00 | 3.00 |
| 1,448.55 | 0.00 | 5.00 |
| 1,449.00 | 0.00 | 1.00 |
| 1,449.60 | 0.00 | 9.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 488
Total Sell Quantity: 568
Shareholding Patterns of Hester Biosciences Limited
Key Trade Statistics of Hester Biosciences Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.47 |
| Traded Value (₹ Cr.) | 6.74 |
| Total Market Cap (₹ Cr.) | 1,219.03 |
| Free Float Market Cap (₹ Cr.) | 552.32 |
| Impact cost | 0.32 |
| Quantity Traded | 46,676.00 |
| Deliverable Quantity | 35,740.00 |
| % of Quantity to Traded | 76.57 |
| Security VaR | 16.31 |
| Index VaR | N/A |
| VaR Margin | 16.31 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 19.81 |
| Face Value | 10 |
Key Price Statistics of Hester Biosciences Limited
The 52-week high for Hester Biosciences Limited was ₹3,379.00, recorded on 26-Jul-2024. On the other hand, the 52-week low stands at ₹1,292.85, with the lowest value recorded on 14-Mar-2024.
The upper band for trading is ₹1,712.50, and the lower band is ₹1,141.70. The price band is 20%.
The stock's daily volatility stands at 2.52, while the annualized volatility is 48.14. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (26-Jul-2024) | 3,379.00 |
| 52 Week Low (14-Mar-2024) | 1,292.85 |
| Upper Band | 1,712.50 |
| Lower Band | 1,141.70 |
| Price Band (%) | 20 |
| Daily Volatility | 2.52 |
| Annualised Volatility | 48.14 |
| Tick Size | 0.05 |
Key Securities Statistics of Hester Biosciences Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 13-Mar-2015 |
| Adjusted P/E | 39.92 |
| Symbol P/E | 39.92 |
| Index | NA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Hester Biosciences Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Hester Biosciences Limited
| Subject | Date |
|---|---|
| Address Change | 18-Feb-2025 |
| Shareholders meeting | 14-Feb-2025 |
| Integrated Filing- Governance | 08-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 01-Feb-2025 |
| Copy of Newspaper Publication | 31-Jan-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 30-Jan-2025 |
| Integrated Filing- Financial | 30-Jan-2025 |
| Press Release | 30-Jan-2025 |
Corporate Actions of Hester Biosciences Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Annual General Meeting | 22-Aug-2024 |
| 10 | Dividend - Rs 6 Per Share | 22-Aug-2024 |
| 10 | Annual General Meeting/Dividend - Rs 8 Per Share | 13-Sep-2023 |
| 10 | Annual General Meeting/Dividend - Rs 10 Per Share | 11-Aug-2022 |
| 10 | Dividend - Rs 10 Per Share | 05-Aug-2021 |
| 10 | Dividend - Rs 6.60 Per Share | 27-Aug-2020 |
| 10 | Dividend - Rs 7 Per Share | 18-Jul-2019 |
| 10 | Interim Dividend - Rs 2 Per Sh | 09-Nov-2018 |
| 10 | Interim Dividend Rs 2 Per Share | 30-Aug-2018 |
| 10 | Dividend- Rs 6 Per Share | 02-Aug-2018 |
| 10 | Interim Dividend - Rs 4/- Per Share (Purpose Revised) | 16-Nov-2017 |
| 10 | Dividend - Rs 2.30 Per Share | 20-Jul-2017 |
| 10 | Interim Dividend Rs 3/- Per Share | 03-Nov-2016 |
| 10 | Dividend - Rs 1.10/- Per Share | 21-Jul-2016 |
| 10 | Interim Dividend - Rs 3/- Per Share (Purpose Revised) | 17-Mar-2016 |
| 10 | Annual General Meeting/ Dividend - Rs 3.10/- Per Share | 10-Sep-2015 |
Board Meetings of Hester Biosciences Limited
Financial Results of Hester Biosciences Limited
Company Directory of Hester Biosciences Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| N/A | Head Office/ Corporate Office | Pushpak, Level One, Panchvati Circle, Motilal Hirabhai Road, | AHMEDABAD |
| N/A | Registered Office | Village - Meda Adraj Taluka - Kadi District - Mehsana | N/A |
| N/A | Transfer Agent | M/s MUFG Intime India Private Limited 5th floor, 506 to 508 Amarnath Business Centre - I Nr. St. Xavier's College Corner Off C G Road, Navarangpura, | AHMEDABAD |
Insider Trading of Hester Biosciences Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | BHUPENDRA VITHALDAS GANDHI HUF | 0 | Sell |
| 7(2) | SHAILA BHUPENDRA GANDHI | 0 | Buy |
| 7(2) | Bhupendra Vittaldas Gandhi HUF | 0 | Sell |
| 7(2) | SANJIV DINESH GANDHI | 0 | Sell |
| 7(2) | BHUPENDRA VITTALDAS GANDHI HUF | 0 | Sell |
| 7(2) | RAJIV DINESH GANDHI | 0 | Buy |
| 7(2) | BHUPENDRA VITTALDAS GANDHI HUF | 0 | Sell |
| 7(2) | Sanjiv Dinesh Gandhi | 0 | Buy |
| 7(2) | Bhupendra Vittaldas Gandhi HUF | 0 | Sell |
| 7(2) | Rajiv Dinesh Gandhi | 0 | Buy |
| 7(2) | Anup Kapadia | 0 | Buy |
| 7(2) | Bhupendra Vittaldas Gandhi HUF | 6829 | Buy |
| 7(2) | Bhupendra Vittaldas Gandhi | 24750 | Buy |
| 7(2) | Shaila Bhupendra Gandhi | 207708 | Buy |
| 7(2) | Madhuri Kapadia | 0 | Sell |
| 7(2) | Yash Rajiv Gandhi | 0 | Buy |
| 7(2) | Rajiv Dinesh Gandhi | 99840000 | Sell |
| 7(2) | Hester Coatings LLP | 99840000 | Buy |
| 7(2) | YASH RAJIV GANDHI | 158084 | Buy |
| 7(2) | Madhuri Kapadia | 1592711 | Sell |
Annual Reports of Hester Biosciences Limited
Investor Complaints of Hester Biosciences Limited
Event Calendar of Hester Biosciences Limited
| Purpose | Details |
|---|---|
| Appointment of Director | To discuss and finalise re-appointment terms of Independent Directors of the Company and other business as per Board agenda. |
| Results/Dividend | To consider and approve the Standalone and Consolidated Audited Financial Results for the financial year ended on March 31, 2015 and for recommendation of dividend, if any. |
| Results | To consider and approve the Unaudited Financial Results for the quarter ended on June 30, 2015. |
| Results | to consider the unaudited financial result for the quarter ended on September 30, 2015. |
| Results | Inter alia, to consider the Unaudited Standalone Financial Results of the Company for the quarter ended December 31, 2015. |
| Dividend | To consider declaration of interim dividend, if any, on the Equity shares of the Company, for the financial year 2015-16. |
| Results | to consider the Audited Standalone and Consolidated Financial Results for the quarter and year ended on March 31, 2016. |
| Qualified Institutional Placement | To consider to raise funds through issue of Equity Shares through Qualified Institutional Placement(QIP) of securities. |
| Results | To Consider the Unaudited Standalone Financial Results for the quarter ended on June 30, 2016. |
| Results/Dividend | To consider Unaudited standalone financial results for the quarter and half year ended on September 30, 2016 and to consider declaration of interim dividend, if any, on equity shares of the company for the financial year 2016-17. |
| Results | To consider the Unaudited Standalone Financial Results for the quarter ended on December 31,2016. |
| Others | with regard to the proposed investments in an existing partnership firm. |
| Results/Dividend | To consider the Audited Standalone and Consolidated Financial Results for the quarter and year ended on March 31, 2017 and to consider declaration of final dividend, if any, on the equity shares of the Company, for the financial year 2016-17. |
| Results | To consider the Unaudited Standalone Financial Results for the quarter ended on June 30, 2017. |
| Results/Dividend | To consider the Unaudited Standalone Financial Results for the quarter and half year ended on September 30, 2017 and to consider declaration of interim dividend, if any, on the Equity shares of the Company, for the financial year 2017-18. |
| Results | To consider the Unaudited Standalone Financial Results for the quarter and nine months ended on December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and final dividend, if any |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2018 and to consider declaration first interim dividend if any, on the equity shares of the Company, for the financial year 2018-19. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2018 and second interim dividend, if any for the FInancial Year 2018-19 |
| Financial Results | To consider and approve the unaudited standalone financial results for the quarter and nine months ended on 31 December 2018 |
| Financial Results/Dividend | To consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31 March 2019 and to consider declaration of the final dividend, if any, on the equity shares of the Company, for the financial year 2018-19. |
| Financial Results | To consider and approve the standalone and consolidated unaudited financial results for the period ended 30 Jun 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Fund Raising | To consider and approve the proposal of raising of funds by way of issue of equity shares, and/or equity linked securities and/or securities convertible into equity shares through Qualified Institutional Placement (QIP) or preferential allotment, subject to the receipt of necessary approvals, in terms of the provisions of the SEBI Regulations and the Companies Act, 2013, as amended from time to time and other applicable laws and other businesses, if any. |
| Financial Results | To consider and approve the financial results for the quarter and nine months ended 31 December 2019 |
| Other business matters | To consider and approve appointment of CFO of the Company |
| Other business matters | To consider and approve the change of Chief Financial Officer (Key Managerial Personnel) of the Company |
| Financial Results/Dividend | To to consider the Standalone and Consolidated Audited Financial Results for the quarter and year ended on 31.03.2020 and to consider declaration of dividend, if any, on the equity shares of the Company, for the financial year 2019-20. We request you to take note of the above. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Fund Raising | The Company has informed the Exchange about addendum ofￂﾠ Board meeting to be held on January 30, 2021 , to consider and approve the financial results for the period ended December 31, 2020 and Fund Raising by the Company |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Other business matters | To consider the borrowings of additional funds as a loan to meeting capex and investment requirements of the Company |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Hester Biosciences Limited has informed the Exchange about Board Meeting to be held on 10-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Hester Biosciences Limited has informed the Exchange about Board Meeting to be held on 04-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Hester Biosciences Limited
Voting Results of Hester Biosciences Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 13-FEB-2025 | Postal Ballot | Shifting of Registered Office of the Company |
| 13-FEB-2025 | Postal Ballot | Shifting of Registered Office of the Company |
| 29-AUG-2024 | AGM | To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended on 31 March 2024 and the reports of the Board of Directors and Auditors thereon |
| 29-AUG-2024 | AGM | Revision in remuneration of Ms. Priya Gandhi (DIN: 06998979) Executive Director (Whole-time) of the Company |
| 29-AUG-2024 | AGM | To ratify the remuneration of Cost Auditors for the financial year ending 31 March 2025 |
| 29-AUG-2024 | AGM | To re-appoint Mr. Ravin Gandhi (DIN: 00438361), who retires by rotation as a Director |
| 29-AUG-2024 | AGM | To declare a dividend on equity shares for the financial year ended 31 March 2024 |
| 29-AUG-2024 | AGM | To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended on 31 March 2024 and the reports of the Auditors thereon |
| 20-SEP-2023 | AGM | To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended on 31 March 2023 and the reports of the Board of Directors and Auditors thereon |
| 20-SEP-2023 | AGM | Appointment of Mr. Jatin Trivedi (DIN: 01618245) as an Independent Director |
| 20-SEP-2023 | AGM | Appointment of Mr. Anil Jain (DIN: 00805735) as an Independent Director |
| 20-SEP-2023 | AGM | To ratify the remuneration of Cost Auditors for the financial year ending 31 March 2024 |
| 20-SEP-2023 | AGM | Re-appointment of the Statutory Auditors |
| 20-SEP-2023 | AGM | To re-appoint Mr. Sanjiv Gandhi (DIN: 00024548), who retires by rotation as a Director |
| 20-SEP-2023 | AGM | To declare a dividend on equity shares for the financial year ended 31 March 2023 |
| 20-SEP-2023 | AGM | To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended on 31 March 2023 and the reports of the Auditors thereon |
| 30-APR-2023 | Postal Ballot | Re-appointment of Ms. Sandhya Patel (DIN: 02215022) as an Independent Director |
| 30-APR-2023 | Postal Ballot | Re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director |
| 30-APR-2023 | Postal Ballot | Re-appointment of Mr. Ashok Bhadakal (DIN: 00981201) as an Independent Director |
| 23-AUG-2022 | AGM | To receive, consider and adopt the audited financial statements and audited consolidatedfinancial statements of the Company for the financial year ended on 31 March 2022 |
FAQs on Hester Biosciences Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.